F. Di Stefano

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo

P. Workman, M. Walton, P. Clarke, 2004, British Journal of Cancer.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

P. Workman, Irina S. Chuckowree, P. Clarke, 2009, Molecular Cancer Therapeutics.

Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.

T. Hickish, P. Clarke, M. Hill, 1994, Cancer research.

The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol

E. Petracci, P. Ostano, A. Ponti, 2017, BMC Cancer.

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

D. Cunningham, P. Clarke, F. Raynaud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

D C Linch, K. Maclennan, D. Cunningham, 1996, Blood.

Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age

F. Frassoni, T. Lamparelli, A. Bacigalupo, 2000, British journal of haematology.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

P. Workman, Irina S. Chuckowree, P. Clarke, 2009, Molecular Cancer Therapeutics.